Tamoxifen metabolites can target both aromatase and estrogen receptors
Indiana University-Purdue University Indianapolis (IUPUI) === Breast cancer remains the most prevalent malignancy diagnosed in women. More than two thirds of all diagnosed breast cancers are estrogen receptor (ER)-positive and are dependent on estrogen signaling. Drugs for the treatment of ER-positi...
Main Author: | Liu, Jinzhong |
---|---|
Other Authors: | Flockhart, David A. |
Language: | en_US |
Published: |
2016
|
Subjects: | |
Online Access: | http://hdl.handle.net/1805/8033 |
Similar Items
-
Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
by: Patricia A. Young, MD, et al.
Published: (2021-04-01) -
Association of Endocrine Therapy and Dementia in Women with Breast Cancer
by: Thompson MR, et al.
Published: (2021-04-01) -
A Role for Estrogen Receptor alpha36 in Cancer Progression
by: Maria Teresa Pagano, et al.
Published: (2020-07-01) -
The use of tamoxifen in the treatment and prevention of breast cancer
by: Magdalena Hołowczuk, et al.
Published: (2019-06-01) -
Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells
by: Derek F. Amanatullah, et al.
Published: (2017-11-01)